Castle Biosciences CSTL

$ 31.61 -6.03%

Quarterly report 2024-Q3
added 11-04-2024

Castle Biosciences Balance Sheet 2011-2024 | CSTL

Annual Balance Sheet Castle Biosciences

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-97.7 M	-121 M	-328 M	-410 M	-73.7 M	20 M	17.4 M	-	-	-	-	-	-
Long Term Debt	25 K	90 K	124 K	-	19.3 M	24.5 M	17.6 M	-	-	-	-	-	-
Long Term Debt Current	1.14 M	1.78 M	1.18 M	-	5.83 M	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	2.76 M	19.3 M	25.7 M	18.9 M	-	-	-	-	-	-
Total Current Liabilities	47.7 M	36.1 M	24.9 M	20.9 M	15.3 M	-	-	-	-	-	-	-	-
Total Liabilities	62.1 M	48.2 M	50.8 M	23.6 M	34.6 M	32.5 M	24.1 M	-	-	-	-	-	-
Deferred Revenue	-	-	-	6.62 M	-	-	-	-	-	-	-	-	-
Retained Earnings	-218 M	-161 M	-93.8 M	-62.5 M	-52.2 M	-57.5 M	-51.1 M	-	-	-	-	-	-
Total Assets	453 M	447 M	463 M	439 M	120 M	22.4 M	9.82 M	-	-	-	-	-	-
Cash and Cash Equivalents	98.8 M	123 M	330 M	410 M	98.8 M	4.48 M	-	-	-	-	-	-	-
Book Value	391 M	399 M	412 M	416 M	85.1 M	-10.1 M	-14.3 M	-	-	-	-	-	-
Total Shareholders Equity	391 M	399 M	412 M	416 M	85.1 M	-56.6 M	-	-	-	-	-	-	-

All numbers in USD currency

Quarterly Balance Sheet Castle Biosciences

	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	10 M	10 M	10 M	-	13.4 M	12.4 M	11.1 M	11.5 M	11.9 M	6.48 M	6.71 M	6.9 M	-	-	-	-	12.5 M	14.7 M	17 M	19.3 M	19.3 M	19.3 M	19.3 M	24.5 M	24.5 M	24.5 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	73.5 M	63.4 M	56 M	62.1 M	50.2 M	46.6 M	41.7 M	48.2 M	46.4 M	36.7 M	47.1 M	50.8 M	22 M	19.6 M	18.7 M	23.6 M	23.6 M	23.6 M	23.6 M	34.6 M	34.6 M	34.6 M	34.6 M	32.5 M	32.5 M	32.5 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	3 M	6.18 M	8.18 M	6.62 M	6.62 M	6.62 M	6.62 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-210 M	-212 M	-221 M	-218 M	-216 M	-209 M	-190 M	-161 M	-140 M	-120 M	-118 M	-93.8 M	-87.4 M	-75.6 M	-66.8 M	-62.5 M	-62.5 M	-62.5 M	-62.5 M	-52.2 M	-52.2 M	-52.2 M	-52.2 M	-57.5 M	-57.5 M	-57.5 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	515 M	487 M	459 M	453 M	436 M	425 M	427 M	447 M	458 M	458 M	444 M	463 M	434 M	436 M	437 M	439 M	439 M	439 M	439 M	120 M	120 M	120 M	120 M	22.4 M	22.4 M	22.4 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	95 M	85.6 M	82.9 M	98.8 M	91.2 M	95.9 M	115 M	123 M	134 M	273 M	309 M	330 M	363 M	368 M	407 M	410 M	410 M	410 M	410 M	98.8 M	98.8 M	98.8 M	98.8 M	4.48 M	4.48 M	4.48 M	-	1.21 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	441 M	424 M	402 M	391 M	386 M	379 M	385 M	399 M	411 M	422 M	397 M	412 M	412 M	416 M	419 M	416 M	416 M	416 M	416 M	85.1 M	85.1 M	85.1 M	85.1 M	-10.1 M	-10.1 M	-10.1 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	441 M	424 M	402 M	391 M	386 M	379 M	385 M	399 M	411 M	422 M	397 M	412 M	412 M	416 M	419 M	416 M	416 M	416 M	416 M	85.1 M	85.1 M	85.1 M	85.1 M	-56.6 M	-56.6 M	-56.6 M	-53.9 M	-50.3 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency